top of page
Target 2 – 1647_edited.jpg

Enabling a new generation of highly targeted genomic medicines for patients with unmet medical needs

Delivering Hope. Promoting Wellness. Transforming Genomic Medicines.

Hopewell Therapeutics is advancing its leading edge tissue-targeted Lipid Nanoparticle (ttLNP) technology to discover, synthesize and develop the next generation of tissue-targeted LNPs. We are a purpose-driven team, working together to bring genomic medicines to patients with high unmet medical needs.

Hopewell Therapeutics Announces $25 Million Seed Financing to Advance Next Generation Lipid Nanoparticles for Targeted Delivery of Genomic Medicines

bottom of page